# OTLK catalysts: Outlook Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/otlk/catalysts

> Outlook Therapeutics, Inc. (OTLK) has 2 upcoming catalysts. The next is the MVASI® (bevacizumab) primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Outlook Therapeutics, Inc. |
| Ticker | OTLK (Nasdaq) |
| SEC CIK | 1649989 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/otlk |

## Cash runway

Cash $11.2M as of 2026-06-30; quarterly burn $21.0M; about 1.6 months of runway at that rate (XBRL company facts, accession 0001104659-26-098415).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2021 | [MVASI® (bevacizumab) topline data readout](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, met | "The topline results reported from NORSE TWO in August 2021 showed that ONS-5010/LYTENAVA met the primary and key secondary endpoints for efficacy with clinically impactful change observed for treated patients." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm)) |
| Aug 2021 | [Lucentis® (ranibizumab) topline data readout](https://sec-api.dev/pdufa/ranibizumab) | OTLK |  | completed, met | "NORSE TWO was our pivotal Phase 3 clinical trial comparing ONS-5010/LYTENAVA to ranibizumab (LUCENTIS) that reported highly statistically significant topline results in August 2021." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm)) |
| Mar 2022 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed | "Separately, in March 2022, we submitted a BLA to the FDA for ONS-5010/LYTENAVA for the treatment of wet AMD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm)) |
| Aug 2022 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm)) |
| Aug 2022 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm)) |
| August 30, 2022 | [MVASI® (bevacizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm)) |
| Aug 2023 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm)) |
| August 29, 2023 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve our BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm)) |
| August 29, 2023 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649989/000155837025001022/otlk-20241231x10q.htm)) |
| Dec 2023 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010 BLA." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm)) |
| Jan 2024 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "In January 2024, the Company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA's requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter ("CRL")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm)) |
| December 27, 2024 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465924131957/tm2431904d1_ex99-1.htm)) |
| Q1 2025 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | scheduled | "Outlook Therapeutics plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/tm256608d1_ex99-1.htm)) |
| February 14, 2025 | [MVASI® (bevacizumab) earnings report](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/tm256608d1_ex99-1.htm)) |
| February 27, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we resubmitted the BLA application for ONS-5010/LYTENAVA on February 27, 2025 and received a CRL on August 28, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm)) |
| February 28, 2025 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "On February 28, 2025, Outlook Therapeutics, Inc. announced that it has resubmitted the Biologics License Application for ONS-5010 to the U.S. Food and Drug Administration." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925018717/tm257885d1_8k.htm)) |
| May 15, 2025 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/tm2515284d1_ex99-1.htm)) |
| Aug 2025 | [Outlook Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed, complete response letter | "Based on our productive meeting with the FDA in September, we believe this resubmission will resolve the outstanding issue highlighted in the Complete Response Letter (CRL) we received in August 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/tm2530088d1_ex99-1.htm)) |
| August 14, 2025 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm)) |
| August 27, 2025 | [Outlook Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | scheduled | "The FDA set a PDUFA goal date of August 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm)) |
| August 27, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "Inc (the "Company") issued a press release announcing that it has completed the requested Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/tm2527376d1_8k.htm)) |
| August 27, 2025 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is August 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm)) |
| Sep 2025 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "Following a September 2025 Type A meeting with the FDA, we resubmitted the ONS-5010/LYTENAVA BLA and have received a Prescription Drug User Fee Act, or PDUFA, goal date of December 31, 2025 for a decision by the FDA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm)) |
| November 3, 2025 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK | retina diseases, today | completed | "On November 3, 2025 we resubmitted the ONS-5010/LYTENAVA BLA and on December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm)) |
| December 19, 2025 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Reports Financial Results for Fiscal Year 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm)) |
| December 30, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761320_20251230.pdf%22)) |
| December 30, 2025 | [Outlook Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed, complete response letter | ""Company") issued a press release announcing that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL)" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/tm2611268d1_8k.htm)) |
| December 31, 2025 | [Outlook Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | scheduled | "Following a Type A meeting in September 2025, the Company resubmitted the BLA on November 3, 2025, and received a Prescription Drug User Fee Act. ("PDUFA") goal date of December 31, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm)) |
| December 31, 2025 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "On December 31, 2025, we reported that we had received a third CRL in which the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, and the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm)) |
| December 31, 2025 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm)) |
| February 17, 2026 | [MVASI® (bevacizumab) earnings report](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for the first quarter fiscal year 2026 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/tm266557d1_ex99-1.htm)) |
| May 15, 2026 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/tm2614868d1_ex99-1.htm)) |
| Jun 2026 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | scheduled | "As a result, Outlook Therapeutics expects to resubmit the ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) in June 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_ex99-1.htm)) |
| July 24, 2026 | [LYTENAVA™ (lytenava) FDA approval](https://sec-api.dev/pdufa/lytenava) | OTLK | wet AMD | completed, approved | "On July 24, 2026, we announced that the FDA approved LYTENAVA for the treatment of wet AMD." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm)) |
| July 24, 2026 | [MVASI® (bevacizumab) FDA approval](https://sec-api.dev/pdufa/bevacizumab) | OTLK | To treat patients with neovascular (wet) age-related macular degeneration | completed, approved | "Lytenava \| bevacizumab-vikg \| 7/24/2026 \| To treat patients with neovascular (wet) age-related macular degeneration" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| July 29, 2026 | [Outlook Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | scheduled | "The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm2618010d1_8k.htm)) |
| August 14, 2026 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "N.J., August 14, 2026 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today reported financial results for the third quarter of fiscal year 2026, ended June 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_ex99-1.htm)) |
| December 2027 | [MVASI® (bevacizumab) primary completion](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | scheduled | "NCT05112861 (A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Outlook Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05112861)) |
| Dec 2027 to Mar 2028 | [MVASI® (bevacizumab) topline data readout](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | scheduled | "NCT05112861 (A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Outlook Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05112861)) |

## Drugs

- [MVASI® (bevacizumab)](https://sec-api.dev/pdufa/bevacizumab): wet amd, retina diseases, today, retinal diseases, today, Ras-mutated Metastatic Colorectal Cancer, Age-Related Macular Degeneration, To treat patients with neovascular (wet) age-related macular degeneration
- [LYTENAVA™ (lytenava)](https://sec-api.dev/pdufa/lytenava): wet amd

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/otlk/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OTLK catalysts: Outlook Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/otlk/catalysts

```bibtex
@misc{secapidev_companies_otlk_catalysts_20261116,
  title        = {OTLK catalysts: Outlook Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/otlk/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_otlk_catalysts_20261116","title":"OTLK catalysts: Outlook Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/otlk/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
